Let’s Talk About Ulcerative Colitis and a Clinical Research Study

Sponsored by Merck 

Let’s Talk About Ulcerative Colitis and a Clinical Research Study

Do you or someone you know have ulcerative colitis (UC)? Ulcerative colitis, a chronic condition that causes inflammation inside the colon, is a common type of inflammatory bowel disease (IBD) that affects approximately 1 million Americans., It’s caused when the body’s immune system mistakenly attacks healthy tissues.^1,2 It’s not yet known what triggers these attacks ― and why UC develops in some people and not in others.¹

From our partner

Do you still have gout symptoms even though you're taking medication? You’re not alone. The Kadence study is a clinical research study for adults with uncontrolled gout. Learn More

Common symptoms of UC include diarrhea, abdominal pain, fatigue, blood in the stool, nausea and sudden weight loss.¹

ATLAS-UC study: Clinical Trial Enrolling Adults With Moderate-to-Severe Active UC

A clinical study is underway that is testing whether an investigational medicine is safe and whether it may work to help resolve or improve symptoms for people with moderate-to-severe active UC. 

Researchers are looking for people to join the ATLAS-UC research study. To qualify, you must be 16-75 years old and have moderate-to-severe active UC. If you are eligible for the clinical study, you:

From our partner

People 16+ years old struggling with lupus: Find out if the PHOENYCS FLY Study may be for you. Study-related care provided at no cost.

• Will receive the investigational study medicine or placebo (looks like the study medicine, but has no active ingredients) and study-related medical exams at no cost. 
• May be paid back for any travel-related study costs, such as bus fare or gas for driving to and from the study site. 

Please note that participants may or may not directly benefit from study participation. The study doctor can answer any questions you may have as well as discuss the possible risks and benefits of participation.

“Clinical trials are designed to help us learn more about how our bodies respond to investigational medicines,” said LaShanda Gordon, clinical trial diversity program lead at Merck. “Different people may have different reactions to the same treatment based on their age, gender, weight, race, ethnicity and other factors. Therefore, it’s important that clinical trials, including trials that are evaluating investigational medicines for ulcerative colitis, include a diverse group of people to ensure the information generated reflects the people affected by the disease.”

Ask your doctor if you may be eligible to participate in this study. For more information, visit www.merckclinicaltrials.com/ulcerativecolitistrial.